Study summary · research use only
Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP) and its therapeutic potential in inflammatory disease (human context, drawing on laboratory and animal-model studies). The authors note that since the late 1970s a number of laboratories have studied the role of VIP in inflammation and immunity, and that these studies highlighted effects of VIP on immune cell activation and function. They state that studies using animal models of disease have indicated VIP has therapeutic and prophylactic potential. The review focuses on the effects of VIP on innate immune cell function and discusses the therapeutic potential for VIP in inflammatory diseases of humans, presenting an overview rather than new experimental data. No numerical results are reported.
Abstract
Since the late 1970s a number of laboratories have studied the role of vasoactive intestinal peptide (VIP) in inflammation and immunity. These studies have highlighted the dramatic effect of VIP on immune cell activation and function, and studies using animal models of disease have indicated that VIP has significant therapeutic and prophylactic potential. This review will focus on the effects of VIP on innate immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.